| Latest Neurochem News Headlines |
| Date | Time | Source | |
| 11/08/2007 | 7:00AM | PRNUS | Neurochem announces important initiatives to provide medical and health benefits to patients
Neurochem will host a live web conference today November 8, 2007, at 8:30 AM ET
LAVAL, QC, Nov. 8 /PRNewswire-FirstCall/ -- Neurochem Inc. (NASDAQ:NRMXNASDAQ: TSX:NASDAQ:NRM) announces today important initiatives including the expansion of its product candidate portfolio, the refocusing of its proprietary R&D assets... More...>> |
| 06/18/2007 | 7:00AM | PRNUS | Neurochem Announces Mandatory and Full Conversion of All Oustanding Senior Subordinated Convertible Notes
LAVAL, QC, June 18 /PRNewswire-FirstCall/ -- Neurochem Inc. (NASDAQ:NRMXNASDAQ: TSX:NASDAQ:NRM) announced today that it has given notice of mandatory conversion into common shares of Neurochem of the full remaining balance of the US$40 million of 5% senior subordinated convertible notes (also known as "junior convertible... More...>> |
| 06/05/2007 | 7:19PM | PRNUS | Neurochem announces it has obtained written consent from its shareholders in connection with its private placement of US$80 mill
LAVAL, QC, June 5 /PRNewswire-FirstCall/ -- Neurochem Inc. ("Neurochem") (NASDAQ:NRMXNASDAQ:TSX:NASDAQ:NRM) announced today that, in connection with its previously announced private placement of US$80 million aggregate principal amount of convertible notes (the "Notes") and warrants the ("Warrants") to purchase common... More...>> |
| 05/02/2007 | 12:50PM | PRNUS | Neurochem Announces Private Placement of US$80 Million Aggregate Principal Amount of 6% Senior Convertible Notes and 5% Senior S
LAVAL, QC, May 2 /PRNewswire-FirstCall/ -- Neurochem Inc. (NASDAQ:NRMXNASDAQ: TSX:NASDAQ:NRM) announced today a private placement of US$80 million aggregate principal amount of convertible notes, consisting of US$40 million of 6% senior convertible notes due in 2027 and US$40 million of 5% senior subordinated convertible... More...>> |
| 04/18/2007 | 3:41PM | PRNUS | HealthShares(TM) Announces Changes to the HealthShares(TM) Neuroscience and Composite Indices
NEW YORK, April 18 /PRNewswire/ -- HealthShares(TM) Inc., an investment company with a series of 20 underlying fund portfolios, today announced it has been informed by Standard & Poor's, the calculating agent for the HealthShares(TM) Indices, that effective at the opening of trading on Monday April 23, 2007, Neurochem... More...>> |
| 02/01/2007 | 7:00AM | PRNUS | Neurochem announcement regarding the completion of its North American phase III clinical trial for tramiprosate (ALZHEMED(TM)) f
LAVAL, QC, Feb. 1 /PRNewswire-FirstCall/ -- Neurochem Inc. (NASDAQ:NRMXNASDAQ: TSX:NASDAQ:NRM) announces the completion of its 18-month North American Phase III clinical trial for tramiprosate (ALZHEMED(TM)) for the treatment of Alzheimer's disease (AD). This study involved 1,052 patients, at 67 clinical sites across... More...>> |
| 01/17/2007 | 5:44PM | PRNUS | Neurochem files shelf prospectus in connection with previously announced equity line of credit facility and convertible notes fi
LAVAL, QC, Jan. 17 /PRNewswire-FirstCall/ -- Neurochem Inc. (NASDAQ:NRMXNASDAQ: TSX:NASDAQ:NRM) announced today that, in accordance with agreements entered into at the time of the establishment, in August 2006, of its equity line of credit facility and the issuance, in November 2006, of US$42.085 million aggregate principal... More...>> |
| 01/16/2007 | 7:00AM | PRNUS | Neurochem announces appointment of John Bernbach to Board of Directors
LAVAL, QC, Jan. 16 /PRNewswire-FirstCall/ -- Neurochem Inc. (NASDAQ:NRMXNASDAQ: TSX:NASDAQ:NRM) announced today the appointment of Mr. John Bernbach to the Company's Board of Directors.
John Bernbach is the president and founder of NTM (Not Traditional Media) Inc., a company that provides advisory services to marketers... More...>> |
| 11/16/2006 | 7:00AM | PRNUS | Neurochem announces initial purchaser's exercise of over-allotment option for the purchase of senior convertible notes
LAVAL, QC, Nov. 16 /PRNewswire-FirstCall/ -- Neurochem Inc. (NASDAQ:NRMXNASDAQ: TSX:NASDAQ:NRM) announced today that it will issue to UBS Securities LLC on or about November 17, 2006, an additional US$2.085 million aggregate principal amount of 6% senior convertible notes with a conversion premium of 20% (which represents... More...>> |
| 11/09/2006 | 3:26PM | PRNUS | Neurochem Announces Closing of Private Placement of US$40 Million Aggregate Principal Amount of 6% Senior Convertible Notes with
LAVAL, QC, Nov. 9 /PRNewswire-FirstCall/ -- Neurochem Inc. (NASDAQ:NRMXNASDAQ: TSX:NASDAQ:NRM) announced today the closing of its previously announced private placement with UBS Securities LLC as initial purchaser, of US$40 million aggregate principal amount of 6% senior convertible notes due in 2026, with a conversion... More...>> |
| 08/18/2006 | 4:34PM | PRNUS | Neurochem announces resignation of a director
LAVAL, QC, Aug. 18 /PRNewswire-FirstCall/ -- Neurochem Inc. (NASDAQ:NRMXNASDAQ: TSX:NASDAQ:NRM) announced today that Mr. Ronald Nordmann has resigned from the Company's Board of Directors. Mr. Nordmann joined the Board in 2002. During his tenure, he served on various committees and acted as the Lead Director for two... More...>> |
| 08/11/2006 | 6:30PM | PRNUS | Neurochem receives approvable letter for eprodisate (Kiacta(TM)) for treatment of AA amyloidosis - Neurochem will host a confer
LAVAL, QC, Aug. 11 /PRNewswire-FirstCall/ -- Neurochem Inc. (NASDAQ:NRMXNASDAQ: TSX:NASDAQ:NRM) announces that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for eprodisate (Kiacta(TM) - formerly Fibrillex(TM)) for the treatment of Amyloid A (AA) amyloidosis.
In its action letter... More...>> |
| 02/16/2006 | 12:22PM | PRNUS | Neurochem Inc. announces exercise of warrant by Picchio Pharma
LAVAL, Feb. 16 /PRNewswire-FirstCall/ -- Neurochem Inc. (NASDAQ:NRMXNASDAQ: TSX:NASDAQ:NRM) announced today that a subsidiary of Picchio Pharma Inc. (Picchio Pharma) has exercised a warrant previously issued under a February 2003 private placement and scheduled to expire on February 18, 2006, generating proceeds to... More...>> |
| 07/25/2005 | 8:52AM | PRNUS | Neurochem Inc. announces exercise of warrant by Picchio Pharma Inc.
Neurochem Inc. announces exercise of warrant by Picchio Pharma
Inc.
LAVAL, July 25 /PRNewswire-FirstCall/ -- Neurochem Inc. (NASDAQ:NRMXNASDAQ:
TSX:NASDAQ:NRM) announced today that a subsidiary of Picchio Pharma Inc.
(Picchio Pharma) has exercised a warrant previously issued under a July 2002
private placement, generating... More...>> |
| 03/09/2005 | 8:53AM | PRNUS | Neurochem Inc. completes public offering of 4 million common shares for gross proceeds of US$61.2 million
Neurochem Inc. completes public offering of 4 million common
shares for gross proceeds of US$61.2 million
MONTREAL, March 9 /PRNewswire-FirstCall/ -- Neurochem Inc. (NASDAQ:NRMXNASDAQ:
TSX:NASDAQ:NRM) announced today that it has completed its formerly announced
public offering of 4 million common shares. The common... More...>> |
| 03/04/2005 | 8:02AM | PRNUS | Neurochem Inc. prices public offering of 4 Million common shares for gross proceeds of US$61.2 Million
Neurochem Inc. prices public offering of 4 Million common shares
for gross proceeds of US$61.2 Million
MONTREAL, March 4 /PRNewswire-FirstCall/ -- Neurochem Inc. (NASDAQ:NRMXNASDAQ:
TSX:NASDAQ:NRM) announced today that its registration statement has become
effective under the U.S. Securities Act of 1933 and that it... More...>> |
| 02/23/2005 | 5:55PM | PRNUS | Neurochem Inc. files preliminary prospectus with Canadian and U.S. Securities authorities for an offering of four million common
Neurochem Inc. files preliminary prospectus with Canadian and
U.S. Securities authorities for an offering of four million common shares
MONTREAL, Feb. 23 /PRNewswire-FirstCall/ -- Neurochem Inc. (NASDAQ:NRMXNASDAQ:
TSX:NASDAQ:NRM) announced today that it has filed a short form preliminary
prospectus with the Canadian... More...>> |
| 04/27/2004 | 1:00PM | PRNUS | Neurochem to present at CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference
Neurochem to present at CIBC World Markets Annual Biotechnology
and Specialty Pharmaceuticals Conference
MONTREAL, April 27 /PRNewswire-FirstCall/ -- Neurochem Inc. announced today
that on Wednesday April 28, 2004, Dr. Francesco Bellini, Chairman and CEO, will
present Neurochem's overall strategy and progress to date... More...>> |
| 04/13/2004 | 10:32AM | PRNUS | Neurochem invited to present findings on Alzheimer drug to Springfield conference
Neurochem invited to present findings on Alzheimer drug to
Springfield conference
Symposium highlights Neurochem's Alzhemed(TM) as one of the most promising
product candidates for the treatment of Alzheimer's Disease
MONTREAL, April 13 /PRNewswire-FirstCall/ -- Neurochem Inc. announced today
that it has been chosen... More...>> |
| 04/08/2004 | 8:00AM | PRNUS | Neurochem Consolidates Operations as it Reaches New Level of Growth
Neurochem Consolidates Operations as it Reaches New Level of
Growth
Acquires State-of-the-Art Facilities for its New Headquarters
MONTREAL, April 8 /PRNewswire-FirstCall/ -- Neurochem Inc. is pleased to
announce today that the Company has signed a conditional agreement to purchase
the Shire BioChem facilities located... More...>> |